FDA Approval of Ziihera in First-Line HER2+ GEA Triggers $250M Milestone Payment to Zymeworks

summarizeSummary

FDA approved Ziihera for first-line HER2+ GEA, triggering a $250M milestone payment from Jazz Pharmaceuticals. Zymeworks has now received $650M from Jazz and remains eligible for up to $1.3B in additional milestones plus royalties.

check_boxKey Events · Product Development and Regulatory · ZYME

• FDA Approves Ziihera in First-Line GEA

  The FDA approved two Ziihera-containing regimens for first-line HER2+ gastroesophageal adenocarcinoma — with tislelizumab plus chemotherapy (IHC 3+ and IHC 2+/ISH+) and with chemotherapy alone (IHC 3+).

• $250M Milestone Payment Earned

  The approval triggers a $250 million milestone payment from Jazz Pharmaceuticals, bringing total upfront and milestone payments received from Jazz to $650 million.

• Up to $1.3B in Additional Milestones

  Zymeworks remains eligible for up to $1.3 billion in additional regulatory and commercial milestones plus tiered royalties of 10% to 20% on Jazz's net sales of zanidatamab.

• BeOne Collaboration Adds $144M Potential

  Under the BeOne Medicines collaboration, Zymeworks has received $81 million to date and remains eligible for up to $144 million in additional milestones plus royalties up to 19.5%.

auto_awesomeAnalysis · ZYME · Life Sciences

The FDA has approved two Ziihera-containing regimens for first-line HER2-positive gastroesophageal adenocarcinoma, triggering a $250 million milestone payment from Jazz Pharmaceuticals. This marks the second FDA approval for zanidatamab in under two years and validates Zymeworks' Azymetric platform. The approval unlocks a major non-dilutive cash infusion and positions Zymeworks for up to $1.3 billion in additional milestones plus 10-20% royalties on Jazz sales. Against the backdrop of the pending $929 million Theravance acquisition and a $45M Q2 loss, this approval materially strengthens Zymeworks' balance sheet and validates its royalty aggregation strategy.